KCT0004019已完成未知
A Phase 1 Clinical Trial to Evaluate Safety and Pharmacokinetic Characteristics after Administration of the SJP003 in Healthy Male Volunteers
Samjin Pharmaceutical0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •1) Healthy adult male volunteers whose age is at least 19 years old and under 45 years of age at screening
- •2) Those with a body weight greater than 50.0 kg and a body mass index (BMI) greater than 18.0 kg / m2 and less than 30.0 kg / m2
- •? BMI (kg / m 2) = body weight (kg) / {height (m)} 2
- •3) Those who do not have congenital or chronic disease requiring treatment and do not have pathologic symptoms or findings as a result of medical examination
- •4) Those who have been found to be suitable for the clinical trial subject by clinical laboratory tests, such as serum test, hematology test, blood chemistry test, urine test, urine drug test etc, and vital signs , physical examination, 12-lead ECG etc., set and performed according to the characteristics of medicines during screening
- •5) Those who has agreed to voluntarily participate in the clinical trial and to observe the subjects' precautions during the clinical trial period after hearing and understanding the details of the clinical trial
排除标准
- •1) Those with clinically significant current or previous history of liver, kidney, nervous system, respiratory system, endocrine system, blood or tumor, urinary, cardiovascular, musculoskeletal or mental illness. In addition, those who have the following symptoms or history
- •? type 1 diabetes or diabetic ketoacidosis
- •? diabetic pre-coma
- •? renal (acute kidney damage and renal dysfunction) and liver dysfunction
- •? heart failure
- •? Those at high risk of bleeding, including severe trauma and surgery
- •2) Those with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •3) Those with a history of gastrointestinal disorders (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple cecal surgery or hernia surgery) that may affect the absorption of drugs
- •4) Those with a history of hypersensitivity reactions or clinically significant hypersensitivity reactions to drugs including dapagliflozin and other drugs (including fibrates, ketoprofen, aspirin, antibiotics, etc)
- •5) At the time of screening, Those whose results of 12-lead ECG show clinically significant findings including the following findings
- •? QTc > 450 msec
- •? PR interval > 200 msec
- •? QRS duration > 120 msec
- •6) When screening, Thowe whose results fo clinical laboratory tests show the following results
- •? AST, ALT, ALP, ?-GTP and bilirubin total exceeding twice the upper limit of normal range in clinical laboratory tests for liver function evaluation
- •? If serum creatinine levels exceed the normal range or eGFR calculated by the Modification of Diet in Renal Disease (MDRD) is less than 60 mL / min / 1.73 m2
- •7) If you have a history of drug abuse or positive urine drug testing
- •8) At the time of screening, after resting for more than 3 minutes, at the vital sign measured in a sitting position, the systolic blood pressure = 150 mmHg or =90 mmHg or the diastolic blood pressure =100 mmHg or =60 mmHg, pulse = 40 times / min or = 100 times / min
- •9) Abnormal diets that can affect the absorption, distribution, metabolism and excretion of drugs or food supplements that can affect drug metabolism
- •10) Within 2 weeks before the first dosing day, those taking any ETC or herbal medicine, including cyclosporine, or within a week, those taking any OTC or vitamin, that may affect the characteristics of the clinical trial drug (However, if the drug does not affect the pharmacokinetic properties of the clinical trial drug, it may be taken at the discretion of the tester.)
- •11) Those taking a drug-metabolizing enzyme inducing and inhibiting drug such as barbiturate drugs within 1 month before the first dosing day
- •12) Those who have received medication within 3 months before the first dosing day by participating in other drug clinical trials or bioequivalence test (However, the criteria for the termination of participation in other clinical trials shall be based on the last day of administration, and the next day shall be calculated as 1 day.)
- •13) Those who donated whole blood within 2 months before the first dosing day or component blood within 1 month, or have received blood transfusions within 1 month
- •14) Those drinking persistently within 6 months before the first dosing day(over 21 units/week, 1 unit = 10 g = 12.5 mL of pure alcohol) or who can't quit from 48 hours before the first dose to PSV
- •ex. 1 cup of Beer (5 %) (250 mL) = 10 g
- •1 cup of Soju (20 %) (50 mL) = 8 g
研究者
相似试验
招募中
不适用
To Assess the Safety and Pharmacokinetic Profile of CKD-516 inj. Administered on A Twice-Weekly Schedule in Patients with Advanced Solid Cancers Failed to Standard TherapyNeoplasmsKCT0000499Chong Kun Dang24
已完成
不适用
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted with MPLA Liposomes, in Healthy, HIV-Uninfected AdultsNL-OMON48531Academisch Medisch Centrum24
尚未招募
1 期
Salmonella Vaccine Immunogenicity and Safety (SaVIS) StudyPACTR202310834458532niversity of Oxford120
已完成
1 期
A clinical trial of influenza(H1N1) vaccine (Live attenuated) in Adults.CTRI/2010/091/000008Serum Institute of India Limited50
已完成
不适用
Clinical trial phase 1 of umbilical cord-derived osteoblast-based cell therapy for osteonecrosis of the femoral headDiseases of the musculoskeletal system and connective tissueKCT0006627CEFO9